墨西哥烟曲霉唑类耐药与cyp51A突变筛查
研究对墨西哥一家三级医疗中心2014至2017年采集的曲霉临床分离株,用以唑类药物的琼脂平板筛查耐药,并测序cyp51A基因编码区与启动子区。39例患者的43株曲霉中3株筛查阳性,2株烟曲霉均检出TR34/L98H突变,烟曲霉中cyp51A突变率为8.3%(2/24)。两例患者均未用过唑类药物,均患侵袭性曲霉病且伏立康唑治疗失败。
要点
- 烟曲霉临床分离株中cyp51A突变率为8.3%(2/24),均为TR34/L98H。
- 两例TR34/L98H突变患者均无既往唑类暴露,提示环境来源耐药。
- 唑类未暴露的侵袭性曲霉病患者若伏立康唑治疗失败,应警惕唑类耐药。
核心结论
- 墨西哥首次报告两例唑类未暴露患者感染携带TR34/L98H突变的唑类耐药烟曲霉,并表现为难治性侵袭性曲霉病。
研究设计与样本
- 回顾性筛查研究,纳入墨西哥一家三级医疗中心2014至2017年临床样本中的曲霉分离株,共筛查39例患者的43株曲霉,用以唑类药物的琼脂平板筛查耐药并对阳性株行cyp51A基因编码区与启动子区测序,临床资料取自病历。
主要发现
- 43株曲霉中3株在含唑类琼脂平板上生长,分别为2株烟曲霉和1株黄曲霉。
- 两株烟曲霉经PCR分析与cyp51A测序均检出TR34/L98H突变。
- 烟曲霉中cyp51A突变率为8.3%(2/24)。
- 两例TR34/L98H突变患者均未用过唑类,均患侵袭性曲霉病,一例为多发性骨髓瘤、另一例为再次肝移植受者,均疾病进展且伏立康唑治疗失败。
临床怎么用
- 对唑类未暴露的侵袭性曲霉病患者,若伏立康唑治疗失败,应考虑唑类耐药可能并送检耐药筛查与cyp51A测序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fungicide exposure in the environment has driven the emergence of azole-resistant Aspergillus fumigatus worldwide. A screening test allows identification of resistant isolates. OBJECTIVES: We screened clinical samples for azole-resistant Aspergillus through azole-containing agar plates and identified mutations in the cyp51A gene of A. fumigatus. METHODS: Aspergillus isolates from clinical samples collected in a tertiary care centre from 2014 to 2017 were screened for azole resistance. Samples were subcultured in azole-containing agar plates. Isolates with a positive screening test were subject to DNA extraction, DNA amplification and sequencing of the cyp51A gene (coding and promoter regions). Clinical data were obtained from medical records. RESULTS: We screened 43 Aspergillus isolates from 39 patients for azole resistance. Three isolates from three patients grew on azole-containing agar plates: two A. fumigatus and one Aspergillus flavus. PCR analysis and cyp51A sequencing identified the TR34/L98H mutation in both A. fumigatus isolates. The prevalence of cyp51A mutations among A. fumigatus was 8.3% (2/24). Both patients with TR34/L98H mutants were azole naive and presented with invasive aspergillosis; one had multiple myeloma and the other was a liver retransplant recipient. They suffered progressive disease and failed voriconazole therapy. CONCLUSIONS: To the best of our knowledge, this is the first report of azole-resistant A. fumigatus with the TR34/L98H mutation in two azole-naive patients with refractory invasive aspergillosis in Mexico.
引用
- Gonzalez-Lara MF, Roman-Montes CM, Diaz-Lomeli P, et al. Azole resistance and cyp51A mutation screening in Aspergillus fumigatus in Mexico. J Antimicrob Chemother. 2019. PMID: 31220262. doi:10.1093/jac/dkz121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。